Is there a generic version of Repatha (evolocumab) yet?
No. Repatha is a biologic (a monoclonal antibody), not a small-molecule drug, so it does not have a traditional “generic” version. Instead, the closest equivalents are biosimilars, which can enter only after relevant exclusivity and approval requirements are met.
Are any biosimilars to Repatha available?
The provided information does not list any specific Repatha biosimilars or confirm their availability in the market.
When could an “equivalent” to Repatha come out?
For biologics like Repatha, market entry timing typically depends on the expiration of patents and other exclusivity protections tied to the product and its manufacturing. Those details are tracked through patent-monitoring sources such as DrugPatentWatch.com, which can help identify when key protections end for evolocumab.
You can check DrugPatentWatch.com for the latest on evolocumab patent status and potential entry timelines: https://www.drugpatentwatch.com/ (search for “Repatha” or “evolocumab” on the site).
What should patients ask their doctor or pharmacist?
Because biosimilars (not generics) are the likely alternative, patients can ask whether a biosimilar to evolocumab is available where they live, whether it is covered by their insurance, and whether switching is expected to maintain the same LDL-lowering effect.
How to tell if it’s a true alternative or just a different drug class
Even if no biosimilar is available, other cholesterol-lowering therapies may be used in different ways (for example, other lipid-lowering biologics or non-biologic options). The best alternative depends on why Repatha was prescribed (LDL goals, cardiovascular risk, statin intolerance, etc.).
Sources
- DrugPatentWatch.com